Company Performance Metrics
Brabant Pharma is a single purpose company developing an oral treatment (“Brabafen”) suitable for use in children with Dravet Syndrome (otherwise known as severe myoclonic epilepsy of infancy).
Dravet Syndrome is a rare form of childhood epilepsy associated with catastrophic seizures resulting in mental and cognitive impairment. Approximately
10%-15% of children die as a direct result. Patients are unresponsive to normal anticonvulsants.
Based on the incidence of Dravet Syndrome, the new treatment will qualify as an Orphan Product in Europe and the United States (US), receiving data exclusivity for 10 and 7 years respectively.
Brabant has licensed exclusive access to new clinical data using up to 20 years of case studies showing exceptional efficacy for the treatment in children with Dravet Syndrome which are frequently unresponsive to standard anticonvulsants.
